These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14733882)

  • 21. [Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C].
    Seifarth C; Benninger J; Böhm BO; Wiest-Ladenburger U; Hahn EG; Hensen J
    Z Gastroenterol; 1999 Mar; 37(3):235-9. PubMed ID: 10234796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?
    Bosi E; Minelli R; Bazzigaluppi E; Salvi M
    Diabet Med; 2001 Apr; 18(4):329-32. PubMed ID: 11437866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura.
    Lotta LA; Degasperi E; Aghemo A; Ferrari B; Peyvandi F; Colombo M
    Transfus Med; 2013 Feb; 23(1):66-68. PubMed ID: 23106108
    [No Abstract]   [Full Text] [Related]  

  • 25. [Patient with HCV chronic hepatitis who has subcutaneous nodules after finishing treatment with pegylated interferon].
    Salgado Ordóñez F; Manteca González R; Palacios Rodríguez S; Godoy Guerrero M
    Rev Clin Esp; 2005 Dec; 205(12):621-2. PubMed ID: 16527184
    [No Abstract]   [Full Text] [Related]  

  • 26. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C.
    Yamazaki M; Sato A; Takeda T; Komatsu M
    Intern Med; 2010; 49(5):403-7. PubMed ID: 20190473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
    Papastergiou V; Skorda L; Lisgos P; Karatapanis S
    Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
    [No Abstract]   [Full Text] [Related]  

  • 28. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
    Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
    Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
    [No Abstract]   [Full Text] [Related]  

  • 30. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 31. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha].
    Schories M; Peters T; Rasenack J; Reincke M
    Dtsch Med Wochenschr; 2004 May; 129(20):1120-4. PubMed ID: 15143453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble interleukin 2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon-alpha 2b and ribavirin.
    Henke H; Schmiegel W; Brechmann T; Voigt E; Griga T
    J Clin Gastroenterol; 2004 Mar; 38(3):301-3. PubMed ID: 15128086
    [No Abstract]   [Full Text] [Related]  

  • 34. Development of reversible diabetes mellitus after cessation of interferon-alpha therapy for chronic hepatitis C infection.
    Tasi TN; Hsieh CH
    N Z Med J; 2004 Dec; 117(1207):U1230. PubMed ID: 15608817
    [No Abstract]   [Full Text] [Related]  

  • 35. Summaries for patients. Re-treating patients with chronic hepatitis C who have not responded to peginterferon-alpha2b.
    Ann Intern Med; 2009 Apr; 150(8):I-34. PubMed ID: 19380849
    [No Abstract]   [Full Text] [Related]  

  • 36. [Adverse reactions of different treatments in chronic hepatitis C].
    Luca C; Grigore L; Vâţă A; Dorobăţ C
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):991-5. PubMed ID: 20191864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
    Leung Y; Urbanski SJ; Schindel L; Myers RP
    Can J Gastroenterol; 2006 Oct; 20(10):661-3. PubMed ID: 17066158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity.
    Yasui S; Fujiwara K; Yokosuka O
    Dig Liver Dis; 2011 Aug; 43(8):666-7. PubMed ID: 21435960
    [No Abstract]   [Full Text] [Related]  

  • 39. Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
    Bachmeyer C; Moguelet P; Gombeaud T; Sbidian E; Aractingi S
    Arch Dermatol; 2011 Oct; 147(10):1232-3. PubMed ID: 22006152
    [No Abstract]   [Full Text] [Related]  

  • 40. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.